Company Profile
Public information reviewed
Relay Therapeutics, Inc.
Canonical company identity and public leadership record.
USNASDAQ: RLAY
Follow
More
- Public sources
- 1 reviewed
- Published leadership records
- 17
- Last reviewed
- Sep 15, 2026
Agent View
Machine representations
Inspect the same governed public record as Markdown, structured data, or a retrieval endpoint.
Markdown
https://registry.alpha.ac/companies/relay-therapeutics-inc.mdRelay Therapeutics, Inc.
Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero.
Record
| Field | Value |
|---|---|
| Representation | alpha-profile-markdown-v3 |
| Protocol | Alpha Governance Facts Protocol 0.1 |
| Schema | alpha.governance.entity.public.v1 |
| Record version | public-1 |
| Canonical entity | alpha:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c |
| Entity type | Company |
| Canonical URL | https://registry.alpha.ac/companies/relay-therapeutics-inc |
| Publication | PUBLISHED |
| Verification | source_reported |
| Verification schema | alpha-verification-states-v1 |
| Ownership | unclaimed |
| Published claims | 20 |
| Claims under review | 1 |
| Evidence records | 3 |
| Conflicts | 0 |
| Conflicts in internal review | 0 |
| Observed | 2026-09-15T20:38:02.503876+00:00 |
| Last reviewed | 2026-09-15T20:38:02.503876+00:00 |
Identity
- Legal name: Relay Therapeutics, Inc.
- Display name: Relay Therapeutics, Inc.
Leadership
- Alexis Borisy: Chairperson and Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Claire Mazumdar: Director. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Claire Mazumdar, Ph.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Douglas S. Ingram: Director. Valid from: 2019-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Habib Joseph Dable: Director. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Linda A. Hill: Director. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Linda A. Hill, Ph.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Lonnel Coats: Director. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Mark Murcko: Director. Valid from: 2016-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Mark Murcko, Ph.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Sanjiv K. Patel, M.D.: Director, President and Chief Executive Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Sekar Kathiresan: Director. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3.
- Sekar Kathiresan, M.D.: Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Donald Bergstrom, M.D., Ph.D.: President, Research & Development. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Peter Rahmer: Chief Corporate Development Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Sanjiv K. Patel, M.D.: President and Chief Executive Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
- Thomas Catinazzo: Chief Financial Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2.
Roles
- PUBLISHED
Governance
- NOT_ASSERTED
Board committees
- PUBLISHED
Financials
- NOT_ASSERTED
Workforce
- NOT_ASSERTED
Market and index context
- PUBLISHED
Legal Name
- Relay Therapeutics, Inc.. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:1.
Headquarters
- US. Publication: UNDER_REVIEW. Verification: source_reported. Assertion: source_reported. Evidence: unlinked, under review.
Entity Status
- Public listing published. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:1.
Published Fact
- US. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:1.
Coverage states
| Field | Value |
|---|---|
| Identity | PUBLISHED |
| Business | PUBLISHED |
| Leadership | PUBLISHED |
| Board and committees | PUBLISHED |
| Governance | NOT_ASSERTED |
| Financials | NOT_ASSERTED |
| Workforce | NOT_ASSERTED |
| Ownership | NOT_ASSERTED |
| Ratings | NOT_PUBLISHED |
| Market and index context | PUBLISHED |
Public sources
- alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:1: Alpha canonical company public projection.
- alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:2: SEC DEF 14A 0001193125-26-186929.
- alpha:evidence:company:6252cfe3-9b38-4c0d-9631-bd0688b7128c:3: DEF 14A rlay-20260424.htm.
Rights
| Field | Value |
|---|---|
| public_retrieval | allowed |
| agent_retrieval | allowed |
| redistribution | not_granted |
| model_training | not_granted |
| commercial_use | not_specified |
| relationship_pathfinding | not_granted |
| direct_contact | not_granted |
Limitations
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
Alternate representations
- Canonical profile
- Public Markdown
- Public JSON
- JSON-LD
- MCP resource:
alpha://companies/relay-therapeutics-incat https://mcp.alpha.ac/mcp